SE448882B - Forfarande for utvinning av myeloperoxidas och farmaceutisk komposition innehallande enzymet - Google Patents
Forfarande for utvinning av myeloperoxidas och farmaceutisk komposition innehallande enzymetInfo
- Publication number
- SE448882B SE448882B SE8005679A SE8005679A SE448882B SE 448882 B SE448882 B SE 448882B SE 8005679 A SE8005679 A SE 8005679A SE 8005679 A SE8005679 A SE 8005679A SE 448882 B SE448882 B SE 448882B
- Authority
- SE
- Sweden
- Prior art keywords
- myeloperoxidase
- oox
- pharmaceutical composition
- manganese
- separation
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 14
- 238000000605 extraction Methods 0.000 title description 2
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 102000003896 Myeloperoxidases Human genes 0.000 claims description 48
- 108090000235 Myeloperoxidases Proteins 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 16
- 210000000265 leukocyte Anatomy 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 238000000926 separation method Methods 0.000 claims description 10
- 244000005700 microbiome Species 0.000 claims description 9
- 238000011084 recovery Methods 0.000 claims description 8
- 102000016938 Catalase Human genes 0.000 claims description 7
- 108010053835 Catalase Proteins 0.000 claims description 7
- 102000007327 Protamines Human genes 0.000 claims description 7
- 108010007568 Protamines Proteins 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 150000001768 cations Chemical class 0.000 claims description 7
- 229940048914 protamine Drugs 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 238000000354 decomposition reaction Methods 0.000 claims description 6
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 6
- 229910001508 alkali metal halide Inorganic materials 0.000 claims description 5
- 150000008045 alkali metal halides Chemical class 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000002523 gelfiltration Methods 0.000 claims description 5
- 238000001179 sorption measurement Methods 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- 239000007900 aqueous suspension Substances 0.000 claims description 4
- 239000011702 manganese sulphate Substances 0.000 claims description 4
- 235000007079 manganese sulphate Nutrition 0.000 claims description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 claims description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000001340 alkali metals Chemical class 0.000 claims description 2
- 239000011565 manganese chloride Substances 0.000 claims description 2
- 235000002867 manganese chloride Nutrition 0.000 claims description 2
- 229940099607 manganese chloride Drugs 0.000 claims description 2
- MIVBAHRSNUNMPP-UHFFFAOYSA-N manganese(2+);dinitrate Chemical compound [Mn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O MIVBAHRSNUNMPP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 14
- 241000700159 Rattus Species 0.000 description 10
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 6
- 241000304886 Bacilli Species 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 5
- 150000002696 manganese Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002070 germicidal effect Effects 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 229920005654 Sephadex Polymers 0.000 description 3
- 239000012507 Sephadex™ Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 101001099460 Homo sapiens Myeloperoxidase Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000051251 human MPO Human genes 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- -1 @ food Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 229920000298 Cellophane Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- WAEMQWOKJMHJLA-UHFFFAOYSA-N Manganese(2+) Chemical compound [Mn+2] WAEMQWOKJMHJLA-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241000282941 Rangifer tarandus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 238000007036 catalytic synthesis reaction Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 150000002697 manganese compounds Chemical class 0.000 description 1
- 229910001437 manganese ion Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000003186 pharmaceutical solution Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
- B65B5/00—Packaging individual articles in containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, jars
- B65B5/02—Machines characterised by incorporation of means for making the containers or receptacles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/814—Enzyme separation or purification
- Y10S435/816—Enzyme separation or purification by solubility
Landscapes
- Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP17210979A JPS5696694A (en) | 1979-12-28 | 1979-12-28 | Separation of myeloperoxidase from human nyelogenic leukocite |
| JP2211380A JPS56118018A (en) | 1980-02-22 | 1980-02-22 | Drug composition containing myeloperoxidase as main constituent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE8005679L SE8005679L (sv) | 1981-06-29 |
| SE448882B true SE448882B (sv) | 1987-03-23 |
Family
ID=26359291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8005679A SE448882B (sv) | 1979-12-28 | 1980-08-12 | Forfarande for utvinning av myeloperoxidas och farmaceutisk komposition innehallande enzymet |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US4306025A (show.php) |
| AT (1) | AT370997B (show.php) |
| DE (1) | DE3031990C2 (show.php) |
| FR (1) | FR2472609A1 (show.php) |
| IN (1) | IN153488B (show.php) |
| SE (1) | SE448882B (show.php) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4937192A (en) * | 1983-05-24 | 1990-06-26 | Cetus Corporation | Fungal chloroperoxidase method |
| US4707447A (en) * | 1983-05-24 | 1987-11-17 | Cetus Corporation | Fungal chloroperoxidase method |
| US4576817A (en) * | 1984-06-07 | 1986-03-18 | Laclede Professional Products, Inc. | Enzymatic bandages and pads |
| SE8500341L (sv) * | 1985-01-24 | 1986-07-25 | Pharmacia Ab | Desinfektionssats samt sett for desinfektion |
| US5460961A (en) * | 1988-06-14 | 1995-10-24 | La Region Wallonne | Human myeloperoxidase and its therapeutic application |
| US5846799A (en) * | 1988-06-14 | 1998-12-08 | La Region Wallone | Human myeloperoxidase and its therapeutic application |
| CA2114163C (en) * | 1993-01-29 | 2002-04-30 | Nobuo Nishiki | Method for stabilizing antigenicity of myeloperoxidase |
| US7015022B2 (en) * | 2002-06-07 | 2006-03-21 | University Of Medicine & Dentistry Of New Jersey | Mammalian catalase-dependent oxidation processes and methods for stimulating oxidative activities |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3947324A (en) * | 1975-04-21 | 1976-03-30 | G. D. Searle And Co. | Method for isolating high purity peroxidase |
| NL7610608A (nl) * | 1976-09-24 | 1978-03-29 | Akzo Nv | Werkwijze voor het stabiliseren van peroxidase- -bevattende composities. |
-
1980
- 1980-08-12 SE SE8005679A patent/SE448882B/sv not_active IP Right Cessation
- 1980-08-20 US US06/179,783 patent/US4306025A/en not_active Expired - Lifetime
- 1980-08-25 DE DE3031990A patent/DE3031990C2/de not_active Expired
- 1980-08-27 FR FR8018581A patent/FR2472609A1/fr active Granted
- 1980-08-28 AT AT0436780A patent/AT370997B/de not_active IP Right Cessation
-
1981
- 1981-07-08 IN IN758/CAL/81A patent/IN153488B/en unknown
- 1981-08-28 US US06/297,418 patent/US4379141A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2472609A1 (fr) | 1981-07-03 |
| US4379141A (en) | 1983-04-05 |
| IN153488B (show.php) | 1984-07-21 |
| FR2472609B1 (show.php) | 1983-10-21 |
| DE3031990A1 (de) | 1981-07-02 |
| SE8005679L (sv) | 1981-06-29 |
| AT370997B (de) | 1983-05-25 |
| ATA436780A (de) | 1982-10-15 |
| US4306025A (en) | 1981-12-15 |
| DE3031990C2 (de) | 1982-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2631470B2 (ja) | 感染防御剤 | |
| JP2003528827A (ja) | カゼイン由来ペプチドおよびその医療用途 | |
| HU227992B1 (en) | Interferon conjugates, process for prepairing them, pharmaceutical compositions, containing them and use of them | |
| JPS5920229A (ja) | 強化されたオプソニン活性を有する組成物 | |
| SE448882B (sv) | Forfarande for utvinning av myeloperoxidas och farmaceutisk komposition innehallande enzymet | |
| CN101254304A (zh) | 用于治疗微生物感染的药物及其用途 | |
| GB2108387A (en) | A pharmaceutical composition containing myeloperoxidase | |
| Satta et al. | Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa, and Streptococcus pneumoniae under in vitro conditions simulating those of serious infections | |
| Craig et al. | The haemolytic uraemic syndrome and bone marrow transplantation | |
| JPH04275231A (ja) | 事故結果として多外傷を有する危険な患者に於て、臓器拒絶の予防及び（又は）処置に、スーパーオキシドジスムターゼを使用する方法 | |
| JPH03135918A (ja) | 免疫賦活剤 | |
| GB2240922A (en) | Bacterial lysate for the treatment of dermatitis | |
| JP2787220B2 (ja) | ウィルス感染防御剤 | |
| JP4014330B2 (ja) | ウイルス感染防御剤 | |
| EP0100366A1 (en) | Agent for treating allergic disease, immunity complex disease, and tumour | |
| RU2166944C2 (ru) | Плазмозамещающий раствор с гемокоррегирующими и иммуномодулирующими свойствами | |
| Calverley et al. | Ventilatory failure after Pasteurella multocida pneumonia | |
| Kozeny et al. | Pneumocystis carinii pneumonia: a lethal complication of “pulse” methylprednisolone therapy | |
| GB2066260A (en) | A method for recovering myeloperoxidase and a pharmaceutical composition containing it | |
| JP3061376B2 (ja) | インフルエンザウィルス感染防御剤 | |
| CA1257203A (en) | Dialysis with monophosphoryl lipid a | |
| JPS5995221A (ja) | 食細胞機能調節作用を有する医薬組成物 | |
| EP0219716A2 (en) | Immunosuppressive agent | |
| GB2125046A (en) | Human leucocyte pepsin like enzyme | |
| JPS6236483B2 (show.php) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8005679-9 Effective date: 19900703 Format of ref document f/p: F |